Corresponding CYP2W1 protein was detected in 40.5% of tumor samples, while all matched normal tissues lacked detectable expression, suggesting selective activation of this enzyme in a significant subset of pediatric STSs and reinforcing its potential as a targeted therapeutic candidate. The gene discussed is CYP2W1; the disease is neoplasm.